Drug search by name

Mitomycin Intravenous and Vincristine liposome Intravenous

Determining the interaction of Mitomycin Intravenous and Vincristine liposome Intravenous and the possibility of their joint administration.

Check result:

Mitomycin Intravenous <> Vincristine liposome Intravenous

Relevance: 26.07.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Medications like vinCRIStine liposome have been reported to occasionally cause shortness of breath and asthma-like attacks, and using them with mitoMYcin may increase the risk. Breathing problems may occur within several minutes to two weeks after treatment. Your doctor may need to monitor you closely and possibly take extra precautions for you to safely use these medications together. Consult with your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Acute shortness of breath and severe bronchospasm have been reported following the administration of vinca alkaloids. These reactions have been encountered most frequently when the vinca alkaloid was used in combination with mitomycin-C. The exact mechanism of the interaction is not known. The reaction may within occur several minutes to 2 weeks after administration of the vinca alkaloid.

MANAGEMENT: The acute shortness of breath and severe bronchospasm may require aggressive treatment (particularly if there is preexisting pulmonary dysfunction). Progressive dyspnea requiring chronic therapy may occur. The vinca alkaloid should not be readministered.

References

Kris MG, Pablo D, Gralla RJ, Burke MT, Prestifillippo J, Lewin D "Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy." Cancer Treat Rep 68 (1984): 1029-31
Israel RH, Olson JP "Pulmonary edema associated with intravenous vinblastine." JAMA 240 (1978): 1585
Ozols RF, Hogan WM, Ostchega Y, Young RC "MVP (mitomycin, vinblastine, and progesterone): a second-line regimen in ovarian cancer with a high incidence of pulmonary toxicity." Cancer Treat Rep 67 (1983): 721-2
Dyke RW "Acute bronchospasm after a vinca alkaloid in patients previously treated with mitomycin." N Engl J Med 310 (1984): 389
Holzer KL, Harrison BR, Luedke SW, Luedke DW "Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin." Drug Intell Clin Pharm 20 (1986): 287-9
Rao SX, Ramaswamy G, Levin M, McCravey JW "Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma." Arch Intern Med 145 (1985): 1905-7
Konits PH, Aisner J, Sutherland JC, Wiernik PH "Possible pulmonary toxicity secondary to vinblastine." Cancer 50 (1982): 2771-4

Mitomycin Intravenous

Generic Name: mitomycin

Brand name: Mutamycin

Synonyms: Mitomycin, MitoMYcin (Systemic)

What is Mitomycin Intravenous?

Vincristine liposome Intravenous

Generic Name: vincristine liposome

Brand name: Marqibo

Synonyms: Vincristine liposome, VinCRIStine (Liposomal)

What is Vincristine liposome Intravenous?

+ Add a drug Remove all

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

The list of popular interactions